The new PharmaPendium has enhanced visualization, intelligent autocomplete and search results that bridge the preclinical to clinical divide.

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.
We'd appreciate your feedback on this new experience.Tell us what you think(opens in new tab/window)
Find the best strategy for your drug candidates’ safety and efficacy. Reduce animal testing. Go to market faster with safer life-transforming treatments for patients. Trusted by the FDA, PMDA and the world’s top 20 pharma companies.
Find powerful preclinical and clinical data and tools for the translation to humans
Benchmark against approved and withdrawn drugs with the same mechanism of action as your drug candidates
Predict:
Adverse effects
Animal models
Clinical endpoints
The more you find and predict, the less animal testing you need.
Predict fast and effective strategies for the success of all regulatory submissions
Use PharmaPendium to minimize regulatory cycling and avoid failing approval
Find information about previous regulatory submissions and profit from precedents to predict agencies’ requirements
"Instead of spending weeks gathering data from scientific articles which would then have to be standardized, we now spend a half day working with PharmaPendium; the hard work is all done for us."
SIMLDC
Scientific information manager, Leading dermatology company
Continuous development and improvement of PharmaPendium has been achieved in collaboration with the FDA for 17 years, as well as with leading pharma partners like Novartis, Sanofi, Merck, Servier and Boehringer Ingelheim.
PharmaPendium is used by:
Toxicologists and safety pharmacologists
DMPK specialists
Clinical researchers
Regulatory affairs experts
Global patient safety experts
Data scientists
PharmaPendium provides you with unique content, all in one place. PharmaPendium data sources include:
Full FDA approval packages
Full EMA approval documents
FDA Advisory Committee Documents
FDA Adverse Event Reporting System (FAERS)
FDA classic collection (covering 1938-1991)
DESI (Drug Efficacy Study Implementation) documents
Meyler's 16th Edition
Mosby's Drug Consult™️
Scientific articles
We extract, organize and connect:
145,349 documents / 3,027,405 pages of FDA Approval documents (including FDA Classic Collection)
4,842 drugs with data in PharmaPendium
2,386,945 extracted safety data lines
2,292,780 extracted PK data lines
582,536 extracted ME data lines
3,813,765 extracted efficacy data lines
184,226 extracted activity data lines
19,705,052 FAERS (post-marketing) reports
18,107 documents / 372,642 pages of EMA Approval documents
20,893 documents / 800,660 pages of FDA Advisory Committees Meetings documents
10,906 documents / 308,149 pages of FDA Classic Collection
2,769 documents / 32,290 pages of DESI documents
PharmaPendium and Embase combined empower you to find additional indications for drug repurposing of unapproved or approved drugs. With the breadth of data in Embase and PharmaPendium, you can find relevant clinical studies and data to predict the requirements of clinical trial design and to mitigate risk. In addition to data on approved drugs in PharmaPendium, Embase provides information on unapproved drugs. Embase covers more than 8,500 scientific journals and millions of abstracts from 11,500 conferences worldwide.